Publications by authors named "Carolina Balderas"
[Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
Christian Omar Ramos-Peñafiel Álvaro Cabrera-García Etta Rozen-Fuller Guadalupe González-León Carolina Balderas
Rev Peru Med Exp Salud Publica
December 2016
Article Synopsis
- A retrospective study assessed the mortality and toxicity of the Hyper-CVAD protocol as a first-line treatment for acute lymphoblastic leukemia in patients under 40, comparing it to the HGMLAL07 regimen.
- Results showed that the Hyper-CVAD regimen had lower complete remission rates (67.7% vs. 81.9%) and survival rates at one year (40% vs. 62%) and two years (18% vs. 34%).
- The study suggests that due to its high cost and toxicity, Hyper-CVAD should primarily be used for patients with relapsed or refractory leukemia.